Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | CHIA | Q9BZP6 | 8/20 | 0.39 |
| ▸ | CHIT1 | Q13231 | 7/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25037188 | 0.78 | GAA (0.53) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL2455907 | 0.71 | GAA (0.69) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL1994355 | 0.70 | GAA (1.00) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL9793471 | 0.69 | GAA (0.67) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL9793417 | 0.67 | GAA (0.62) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL20476058 | 0.67 | MTOR (0.38) | — | |
| SCHEMBL31214557 | 0.67 | GAA (0.57) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL31214493 | 0.65 | GAA (0.63) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL31387185 | 0.62 | GAA (0.56) | GAAMAPTALDH1A1GFERCHIA | |
| SCHEMBL15400038 | 0.58 | MAPT (0.45) | GAAMAPTALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117425657-A | Triazolo-pyrimidine analogs for the treatment of diseases associated with inhibition of Wonna syndrome RECzochralski enzyme (WRN) | 诺华股份有限公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046859-A1 | Bicyclic Compounds and their Uses | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 | GAA 2524/4885MAPT 2519/4885ALDH1A1 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.